



AGA (h2): 293T Lysate: sc-170753

BACKGROUND

AGA (aspartylglucosaminidase) is a 346 amino acid precursor protein that belongs to the Ntn-hydrolase family and is cleaved to produce an α chain and a β chain. Localized to the lysosome, AGA functions as a heterotetramer composed of two α and two β chains that work together to cleave the GlcNAc-Asn bond that joins oligosaccharides to target glycoproteins. Defects in the gene encoding AGA are the cause of aspartylglucosaminuria (AGU), a lysosomal storage disease that is characterized by severe mental retardation and mild connective tissue abnormalities. The gene encoding AGA maps to human chromosome 4q34.3, which encodes nearly 6% of the human genome and has the largest gene deserts (regions of the genome with no protein encoding genes) of all of the human chromosomes.

REFERENCES

1. Mononen, I., Fisher, K.J., Kaartinen, V. and Aronson, N.N. 1993. Aspartylglucosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation. *FASEB J.* 7: 1247-1256.
2. Tollersrud, O.K., Heiskanen, T. and Peltonen, L. 1994. Human leucocyte glycosylasparaginase is an α/β -heterodimer of 19 kDa α subunit and 17 and 18 kDa β subunit. *Biochem. J.* 300: 541-544.
3. Saarela, J., Laine, M., Oinonen, C., Schantz, C., Jalanko, A., Rouvinen, J. and Peltonen, L. 2001. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. *Hum. Mol. Genet.* 10: 983-995.
4. Saarela, J., Oinonen, C., Jalanko, A., Rouvinen, J. and Peltonen, L. 2004. Autoproteolytic activation of human aspartylglucosaminidase. *Biochem. J.* 378: 363-371.
5. Saarela, J., von Schantz, C., Peltonen, L. and Jalanko, A. 2004. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase. *Hum. Mutat.* 24: 350-351.
6. Jackson, M., Clayton, P., Grunewald, S., Keir, G., Mills, K., Mills, P., Winchester, B., Worthington, V. and Young, E. 2005. Elevation of plasma aspartylglucosaminidase is a useful marker for the congenital disorders of glycosylation type I (CDG I). *J. Inherit. Metab. Dis.* 28: 1197-1198.
7. Saito, S., Ohno, K., Sugawara, K., Suzuki, T., Togawa, T. and Sakuraba, H. 2008. Structural basis of aspartylglucosaminuria. *Biochem. Biophys. Res. Commun.* 377: 1168-1172.
8. Michelakakis, H., Moraitou, M., Mavridou, I. and Dimitriou, E. 2009. Plasma lysosomal enzyme activities in congenital disorders of glycosylation, galactosemia and fructosemia. *Clin. Chim. Acta* 401: 81-83.
9. Online Mendelian Inheritance in Man, OMIM™. 2009. Johns Hopkins University, Baltimore, MD. MIM Number: 208400. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: AGA (human) mapping to 4q34.3.

PRODUCT

AGA (h2): 293T Lysate represents a lysate of human AGA transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

AGA (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive AGA antibodies. Recommended use: 10-20 μ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.